---
title: "JAFRON: Net profit in 2024 is expected to increase by 83% to 97% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225676832.md"
description: "JAFRON expects its net profit attributable to the parent company in 2024 to reach 800 million to 860 million yuan, a year-on-year increase of 83% to 97%. The company's external policy environment has improved, maintaining a technological and market-leading advantage in the field of blood perfusion, with good business development in areas such as nephrology, hepatology, and critical care. Operating revenue has increased year-on-year. At the same time, the company has implemented measures to improve efficiency and reduce costs, resulting in a decrease in the period expense ratio, driving a significant increase in net profit"
datetime: "2025-01-21T11:20:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225676832.md)
  - [en](https://longbridge.com/en/news/225676832.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225676832.md)
generator: "portal-rs"
---

# JAFRON: Net profit in 2024 is expected to increase by 83% to 97% year-on-year

JAFRON announced its performance forecast on the evening of January 21, expecting a net profit attributable to the parent company of 800 million to 860 million yuan in 2024, a year-on-year increase of 83% to 97%. During the reporting period, the external policy environment for the company improved to some extent. The company continues to leverage its technological and market leadership in the field of blood perfusion, with good business development trends in areas such as nephrology, hepatology, and critical care. This has resulted in a year-on-year increase in the company's operating revenue. The company conducts various business activities based on the principle of increasing efficiency and reducing costs, leading to a year-on-year decrease in the period expense ratio, and thus a significant year-on-year increase in net profit attributable to shareholders of the listed company

### Related Stocks

- [300529.CN](https://longbridge.com/en/quote/300529.CN.md)
- [301252.CN](https://longbridge.com/en/quote/301252.CN.md)
- [688603.CN](https://longbridge.com/en/quote/688603.CN.md)
- [688507.CN](https://longbridge.com/en/quote/688507.CN.md)

## Related News & Research

- [Mark Cuban Says 'We Will Always Pay More' as PBMs Set Drug Prices, Calls Healthcare Conglomerates 'Too Big to Care'](https://longbridge.com/en/news/297034426.md)
- [Adaptyv Bio raises $40 million Series A as ACE Ventures joins round](https://longbridge.com/en/news/297004059.md)
- [Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application](https://longbridge.com/en/news/296995766.md)
- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)
- [14:02 ETProject Lifesaver Partners With FaceTec to Identify At-Risk Children and Adults](https://longbridge.com/en/news/297076808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**